Moreover, in the N9831/B31 study (25), which included 4046 patients with HER2-positive breast cancer, the 10-year DFS and OS rates were 73.7% and 84% in the treatment group with AC-T, and 62.2% and 75.2% in the treatment group without AC-T, respectively. This evidence concerns the gene ERBB2 and breast carcinoma.